COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

Objective To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease.Methods We conducted a 12-month, prospective, non-randomised, open-label, comparative trial of adults with either rheumatoid arthritis (RA, n=131) on stable treatm...

Descripción completa

Detalles Bibliográficos

Autores principales:	Emmanouil Rampakakis, Paul R Fortin, Sasha Bernatsky, Louis Bessette, Ines Colmegna, Elizabeth Hazel, Laëtitia Michou, Mary-Ann Fitzcharles, Louis Flamand, Emmanuelle Rollet-Labelle, Marc-André Langlois, Valeria Valerio, Nathalie Amiable, Mariana Useche, Deirdre McCormack, Pantelis Panopalis
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMJ Publishing Group 2023-10-01
Colección:	RMD Open
Acceso en línea:	https://rmdopen.bmj.com/content/9/4/e003400.full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!